Opko Health Inc (OPK)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 11:06 AM ET
Opko Health Inc (OPK) Financials: Revenue, Profit and Cash Flow
Opko Health reported revenue of $606.88M for the fiscal year ended Dec 31, 2025, down 14.9% from the year before. That year, net income was -$225.68M with a net margin of -37.2%, operating cash flow was -$178.54M and free cash flow was -$190.82M. The quarter ended Sep 30, 2026 had revenue of $65.41M and net income of -$53.53M.
Revenue and Margins
The operating margin was -19.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $1.12B, a compound annual decline of 6.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $606.88M | -14.9% | 33.9% | -19.3% | -37.2% |
| Dec 2024 | $713.14M | -17.4% | 30.6% | -21.3% | -7.5% |
| Dec 2023 | $863.50M | -14.0% | 36.8% | -18.2% | -21.9% |
| Dec 2022 | $1.00B | -43.4% | 28.7% | -22.5% | -32.7% |
| Dec 2021 | $1.77B | +23.6% | 32.8% | 1.1% | -1.7% |
| Dec 2020 | $1.44B | +59.1% | 37.7% | 4.0% | 2.1% |
| Dec 2019 | $901.93M | -8.9% | 36.5% | -30.4% | -34.9% |
| Dec 2018 | $990.27M | -43.4% | 38.9% | -17.3% | -15.5% |
| Dec 2017 | $1.75B | +56.5% | 64.5% | -15.8% | 82.5% |
| Dec 2016 | $1.12B | N/A | 45.3% | -8.6% | -4.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.88M | $713.14M | $863.50M | $1.00B | $1.77B | $1.44B | $901.93M | $990.27M | $1.75B | $1.12B |
| Cost of revenue | $400.94M | $494.63M | $545.37M | $715.98M | $1.19B | $894.41M | $572.48M | $604.64M | $620.13M | $611.48M |
| Gross profit | $205.94M | $218.51M | $318.13M | $288.22M | $581.52M | $541.00M | $329.45M | $385.63M | $1.13B | $506.01M |
| Research and development | $124.03M | $105.21M | $89.59M | $73.89M | $76.85M | $75.32M | $117.87M | $125.59M | $126.44M | $113.87M |
| Operating income | -$117.41M | -$152.06M | -$157.02M | -$226.25M | $18.75M | $57.71M | -$274.05M | -$171.20M | -$276.44M | -$96.55M |
| Net income | -$225.68M | -$53.22M | -$188.86M | -$328.40M | -$30.14M | $30.59M | -$314.93M | -$153.04M | $1.44B | -$48.36M |
| EBITDA | -$50.85M | $128.83M | -$68.28M | N/A | $84.33M | $156.67M | -$190.36M | -$69.09M | -$163.62M | $6.94M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.41M | $163.58M | $124.20M | $148.45M | $56.42M | $156.81M | $149.95M | $183.64M | $173.63M | $182.19M | $173.69M | $181.91M |
| Gross profit | $42.06M | $80.02M | $45.76M | $64.03M | $35.05M | $49.40M | $42.62M | $84.66M | $40.13M | $51.65M | $42.07M | $44.71M |
| Operating income | -$31.41M | -$6.97M | -$51.02M | -$38.32M | -$33.55M | -$59.98M | -$67.17M | -$33.14M | $14.22M | -$61.67M | -$71.47M | -$69.05M |
| Net income | -$53.53M | -$8.42M | -$54.85M | -$31.26M | $21.63M | -$148.44M | -$67.61M | $14.03M | $24.89M | -$10.30M | -$81.84M | -$66.48M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $341.70M by $27.37M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | $2.40B | $2.47B | $2.31B | $2.45B | $2.59B | $2.77B |
| Current assets | $581.88M | $662.09M | $309.48M | $394.52M | $823.01M | $523.18M | $324.05M | $317.73M | $348.86M | $483.60M |
| Cash and equivalents | $369.07M | $431.94M | $95.88M | $153.19M | $134.71M | $72.21M | $85.45M | $96.47M | $91.50M | $168.73M |
| Total liabilities | $663.98M | $834.76M | $622.48M | $605.61M | $714.59M | $801.51M | $694.51M | $659.78M | $746.33M | $674.81M |
| Short-term debt | $10.25M | $15.02M | $27.29M | $36.59M | $14.70M | $36.18M | $9.62M | $37.41M | $11.93M | $11.98M |
| Long-term debt | $331.45M | $419.18M | $214.32M | $210.37M | $187.94M | $221.99M | $211.21M | $57.30M | $29.16M | $43.70M |
| Shareholder equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B | $1.67B | $1.61B | $1.79B | $1.84B | $2.09B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.88B | $1.83B | $1.86B | $1.93B | $2.00B | $1.97B | $2.13B | $2.20B | $2.26B | $1.98B | $1.97B | $2.01B |
| Total liabilities | $764.08M | $645.29M | $652.19M | $663.99M | $690.02M | $676.09M | $816.66M | $834.76M | $852.69M | $584.55M | $721.21M | $622.48M |
| Cash and equivalents | $390.22M | $300.76M | $341.88M | $369.07M | $415.20M | $271.72M | $436.00M | $431.94M | $406.40M | $40.58M | $75.64M | $95.88M |
| Shareholder equity | $1.12B | $1.18B | $1.20B | $1.27B | $1.31B | $1.30B | $1.31B | $1.37B | $1.40B | $1.40B | $1.25B | $1.39B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$178.54M | -$183.49M | -$28.20M | -$95.19M | $38.34M | $39.48M | -$172.52M | -$109.14M | -$92.08M | $32.05M |
| Capital expenditures | $12.28M | $25.01M | $16.27M | $24.58M | $32.16M | $33.68M | $12.74M | $27.86M | $46.52M | $18.55M |
| Free cash flow | -$190.82M | -$208.50M | -$44.47M | -$119.77M | $6.18M | $5.79M | -$185.26M | -$137.00M | -$138.60M | $13.50M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $3.00K | N/A | $0 | $0 |
| Share repurchases | $47.04M | $90.22M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $230.30M | $352.21M | -$18.20M | $91.04M | $35.95M | -$18.33M | -$13.27M | -$26.12M | -$46.67M | -$20.70M |
| Financing cash flow | -$118.06M | $184.17M | -$11.30M | $22.97M | -$10.35M | -$35.08M | $175.25M | $140.91M | $61.04M | -$35.20M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$36.31M | -$43.50M | -$19.31M | -$25.92M | -$34.65M | -$83.42M | -$34.55M | -$44.41M | -$77.08M | -$26.43M | -$35.57M | -$38.29M |
| Capital expenditures | $2.79M | $3.00M | $1.83M | $2.67M | $3.13M | $3.28M | $3.19M | $5.41M | $7.94M | $7.22M | $4.44M | $3.02M |
| Free cash flow | -$39.10M | -$46.50M | -$21.14M | -$28.59M | -$37.78M | -$86.70M | -$37.75M | -$49.82M | -$85.02M | -$33.65M | -$40.01M | -$41.32M |
Frequently Asked Questions About OPK
What is Opko Health's annual revenue?
Opko Health reported revenue of $606.88M for the fiscal year ended Dec 31, 2025.
How fast is Opko Health's revenue growing?
Revenue was down 14.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -15.5%.
Is Opko Health profitable?
No. Opko Health reported net income of -$225.68M for the fiscal year ended Dec 31, 2025, with a net margin of -37.2%.
How much free cash flow does OPK generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$178.54M minus capital expenditures of $12.28M produced free cash flow of -$190.82M.
How much debt does Opko Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $331.45M, short-term debt of $10.25M and cash and equivalents of $369.07M.
OPK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts